Catalent has signed an agreement with Bone Therapeutics to acquire its cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including all of its assets located in Gosselies, Belgium. The transaction is expected to close in November 2020.

Catalent and BrainStorm Cell Therapeutics Inc announced an agreement for the manufacture of NurOwn®, BrainStorm’s autologous cellular therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neuron disease.

Catalent today announced that Jesse Trekker, Ph.D., Business Director, Strategic Partnerships, Catalent Cell & Gene Therapy, will present at the Allogeneic Cell Therapies Summit, which will take place virtually on 26 – 28 October, 2020.

Catalent today announced that it will be participating in several roundtables alongside other leading industry experts at the CPhI Festival of Pharma, which is taking place virtually between Oct. 5 – 16, 2020.

Catalent today announced that it has acquired a new manufacturing facility in Bloomington, Indiana, to create a North American center of excellence for early-phase clinical biologics formulation development and drug product fill/finish services.

Catalent today announced that George Buchman, Ph.D., Vice President, Preclinical & Process Development, will present at the World Vaccine Congress, which will take place virtually on Sept. 28 – October 1, 2020.

T-knife and Catalent today announced they have signed an agreement to provide technology transfer and CGMP clinical manufacturing of T-knife’s T1367 T-cell receptor (TCR) program.

Catalent today announced that it will present at the upcoming BioProcess International virtual conference, taking place between Sept. 21 – 25, 2020.

Catalent today announced that it is investing $130 million to add five additional Phase 3 through commercial-scale manufacturing suites to its gene therapy campus in Harmans, Maryland.